New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
08:10 EDTCOV, MDTMedtronic price target raised to $73 from $66 at Oppenheimer
Oppenheimer increased its price target on Medtronic (MDT), citing cost savings and tax benefits from the company's acquisition of Covidien (COV). The firm keeps an Outperform rating on Medtronic.
News For MDT;COV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
08:28 EDTMDTMedtronic sees U.S. approval for IMPACT Admiral balloon in Q1
Subscribe for More Information
07:20 EDTMDT, COVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS $4.00-$4.10, consensus $4.05
Narrows FY15 revenue guidance to up 4%-5% from 3%-5%.
07:17 EDTMDTMedtronic reports Q2 EPS 96c, consensus 96c
Subscribe for More Information
November 17, 2014
15:16 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
08:57 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 28, December is at 21, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 16, 2014
14:08 EDTMDTDaVita announces collaboration with Medtronic
DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA) and leading provider of kidney care services, announced a collaboration with Medtronic (MDT) to better understand cardiovascular health in end stage renal disease, ESRD patients. The collaboration will focus on developing a pilot program using Medtronic's Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis. "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis," said Ven Manda, vice president, Renal Care Solutions at Medtronic. "We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients." "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients," said Mahesh Krishnan, vice president for clinical innovation and public policy for DaVita HealthCare Partners. "Through the collaboration we expect to utilize innovative monitoring technology and data from our DaVita Kidney Care information systems across the country. This effort is poised to improve the lives of patients by proactively detecting and preventing cardiac complications."
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
12:43 EDTCOV, MDTMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTMDT, COVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTMDT, COVMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
November 12, 2014
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 11, 2014
07:24 EDTMDT, COVMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:10 EDTMDTMedtronic announces Japanese approval, launch of Evera MRI SureScan ICD
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use